Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: Lessons learned from experimental and clinical studies

Shock

Volumn 7, Issue 4, 1997, Pages 235-246

  Kilbourn, Robert G ^a   Szabó, Csaba ^b   Traber, Daniel L ^c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SCAVENGER;

ANIMAL; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE MODEL; DOG; DRUG ANTAGONISM; DRUG COMBINATION; HUMAN; METABOLISM; MOUSE; RABBIT; RAT; REVIEW; RODENT; SEPTIC SHOCK;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DOGS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FREE RADICAL SCAVENGERS; HUMANS; MICE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RABBITS; RATS; RODENTIA; SHOCK, SEPTIC;

EID: 0031112190     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199704000-00001     Document Type: Article

References (119)

1. Zeigler EJ, Fisher CJ, Sprung CL, et al: Treatment of Gram negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. New Engl J Med 324:429-436, 1991.
2. McCloskey R, Straube R, Sanders C, Smith S, Smith C: The CHESS Trial Study Group: Treatment of septic shock with human monoclonal antibody HA-1A. Ann Int Med 121:1-5, 1994.
3. Casey L, Balk R, Bone R: Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Int Med 119:771-778, 1993.
4. Dofferhoff A, Bom V, de Vries-Hospers H, et al: Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute phase proteins during the treatment of severe sepsis in humans. Crit Care Med 20:185-192, 1992.
5. Kilbourn R, Griffith O: Overproduction of nitric oxide in cytokinemediated and septic shock. J Natl Cancer Inst 84:827-831, 1992.
6. Stone R: Search for sepsis drugs goes on despite past failures. Science 264:365-367, 1994.
7. Fisher CJ, Slotman GJ, Opal SM, et al: The Sepsis Study Syndrome Study Group. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22:12-21, 1994.
8. Glauser M, Zanetti G, Baumgartner J, Cohen J: Septic shock: Pathogenesis. Lancet 338:7372-7373, 1991.
9. Cross A, Opal S, Sadoff J, Gemski P: Mini review: Choice of bacteria in animal models of sepsis. Infect Immun 61:2741-2747, 1993.
10. Bone R: The Pathogenesis of sepsis. Ann Int Med 115:457-469, 1991.
11. Palmer RMJ: The discovery of nitric oxide in the vessel wall: A unifying concept in the pathogenesis of sepsis. Arch Surg 128:396-401, 1993.
12. Thiemermann C: Role of the L-arginine-nitric oxide pathway in circulatory shock. Adv Pharmacol 28:45-79, 1994.
13. Szabó C: Alterations in nitric oxide production in various forms of circulatory shock: New Horizons 3:2-32, 1995.
14. Kilbourn RG: Animal models of sepsis. In Feelisch M, Stamler J (eds): Methods in Nitric Oxide Research. Sussex England and Chichester UK: John Wiley and Sons, Ltd., pp 619-630, 1996.
15. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 87:3629-3632, 1990.
16. Kilbourn RG, Gross SS, Lodato RF, et al: Inhibition of interleukin-lainduced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-la-induced hypotension by N-omega-L-aminoarginine. J Natl Cancer Inst 84:1008-1016, 1992.
17. G-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 172:1132-1138, 1990.
18. G-methyl-Larginine, an inhibitor of nitric oxide formation, reverses IL-2 mediated hypotension in dogs. J Appl Physiol 76:1130-1137, 1994.
19. Julou-Schaeffer G, Gray G, Fleming I, Schott C, Parrat J, Stoclet J: Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 259:H1038-H1043, 1990.
20. Fleming I, Gray G, Julou-Schaeffer G, Parrat J, Schott C, Stoclet J: Impaired vascular reactivity in the rat following endotoxin treatment can be endothelium independent, yet involves the L-arginine pathway. J Physiol 423:18P, 1990.
21. Nava E, Palmer R, Moncada S: Inhibition of nitric oxide synthesis in septic shock: How much is beneficial? Lancet 338:1555-1557, 1991.
22. Szabó C, Southan G, Thiemermann C: Beneficial effects and improved survival in rodent models of septic shock with S-methyl-isothiourea sulfate, a novel potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci USA 91:12472-12476, 1994.
23. Hinder F, Booke M, Traber L, et al: Nitric oxide synthase inhibition during experimental sepsis improves renal excretory function in the presence of chronically elevated atrial naturetic peptide: Crit Care Med 24:131-136, 1996.
24. Booke M, Hinder F, McGuire R, Traber L, Traber D: Nitric oxide synthase inhibition versus norepinephrine in ovine sepsis: Effects on regional blood flows. Shock 5:362-370, 1996.
25. Klemm P, Thiemermann C, Winklmaier G, Martorana P, Henning R: Effects of nitric oxide synthase inhibition combined with nitric oxide inhalation in a porcine model of endotoxic shock. Br J Pharmacol 114:363-368, 1995.
26. Teale D, Atkinson A: Inhibition of nitric oxide synthesis improves survival in a murine peritonitis model of sepsis that is not cured by antibiotics alone. J Antimicrob Chemother 30:839-842, 1992.
27. G-Monomelhyl-L-arginine (NMA) restores arterial blood pressure but reduces cardiac output in a canine model of endotoxic shock. Biochem Biophys Res Commun 178:1135-1140, 1991.
28. Mulder M, VanLambalgen A, Huisman L: Protective role of NO in the regional hemodynamic changes during acute endotoxemia in rats. Am J Physiol 266:H1558-H1564, 1994.
29. Pastor C, Teisseire B, Vicaut E: Effects of L-arginine and L-nitro arginine treatment on blood pressure and cardiac output in a rabbit endotoxin shock model. Crit Care Med 22:465-469, 1994.
30. Henderson J, Statman R, Cunningham J: The effects of nitric oxide inhibition on regional hemodynamics during hyperdynamic endotoxemia. Arch Surg 129:1271-1275, 1994.
31. Cobb P, Natanson C, Huffman W: Differential hemodynamic effects of L-NMMA in endotoxemic and normal dogs. Am J Physiol 268:H1634-H1642, 1995.
32. Stratman R, Cheng W, Cunningham JN: Nitric oxide inhibition in the treatment of the sepsis syndrome is detrimental to tissue oxygenation. J Surg Res 57:93-98, 1994.
33. Schumacker P, Kazaglis J, Connolly H: Systemic and gut oxygen extraction during endotoxemia: Role of nitric oxide synthesis. Am J Respir Crit Care Med 151:107-115, 1995.
34. Mitaka C, Hirara Y, Ichikawa K: Effects of nitric oxide inhibitor on hemodynamic change and oxygen delivery in septic dogs. Am J Physiol 268:H2017-H2023, 1995.
35. G-monomethyl-L-arginine inhibits endotoxin-induced nitrite/ nitrate biosynthesis while promoting hepatic damage. J Leukocyte Biol 48:565-569, 1990.
36. Minnard E, Shou J, Naama H: Inhibition of nitric oxide synthesis is detrimental during endotoxemia. Arch Surg 129:142-148, 1994.
37. Tiao GRJ, Ogle C: Detrimental effects of nitric oxide synthase inhibition may be caused by high levels of tumor necrosis factor and interleukin 6. Surgery 116:332-338, 1994.
38. Fukahatsu K, Saito H, Fukushima R: Detrimental effects of a nitric oxide synthase inhibitor (Nω-nitro-L-arginine methyl ester) in a murine sepsis model. Arch Surg 130:410-414, 1994.
39. G-Amino-L-arginine, an inhibitor of nitric oxide synthase, increases lethality in canine endotoxic shock: Clin Res 39:321 A, 1991.
40. Hinshaw L: The role of glucose in endotoxin shock. Circ Shock 3:1-9, 1976.
41. Reicher JR: Historical perspective of endotoxin effects on hemodynamics in animals. In Passmore JC, Reichard SM, Reynolds DG, et al. (eds): Perspectives in Shock Research: Metabolism, Immunology, Mediators, and Models. New York, NY: Alan Liss, Inc., 1989, pp 77-94.
42. Thiemermann C, Vane J: Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 182:591-595, 1990.
43. Christou NV, Tellado RJ: Immunological mediators. Prog Clin Biol Res 264:115-124, 1988.
44. Szabó C, Mithchell J, Thiemermann C, Vane JR: Nitric oxide mediated hyporeactivity to noradrenaline precedes nitric oxide synthase induction in endotoxin shock. Br J Pharmacol 108:786-792, 1993.
45. G-monomethyl-L-arginine. J Immunol 146:1294-1302, 1991.
46. Ding A, Nathan C, Stuehr D: Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. J Immunol 141:2407-2412, 1988.
47. Hibbs J, Taintor R, Vavrin Z, Rachlin E: Nitric oxide: A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157:87-94, 1988.
48. Vouldoukis I, Riveros-Moreno V, Dugas B, et al: The killing of Leishmania major by human macrophages is mediated by nitric oxide induction after ligation of the Fc epsilon RII/CD23 surface antigen. Proc Natl Acad Sci USA 92:7804-7808, 1995.
49. Aranow J, Zhuang J, Wang H, Larkin V, Smith M, Fink M: A selective inhibitor of inducible nitric oxide synthase prolongs survival in a rat model of bacterial peritonitis: Comparison with two nonselective strategies. Shock 5:116-121, 1996.
50. Evans T, Carpenter A, Silva A: Inhibition of nitric oxide synthase in experimental Gram-negative sepsis. J Infect Dis 169:343-349, 1994.
51. Olson N, Kruse-Elliott K, Dodam J: Systemic and pulmonary reactions in swine with endotoxemia and Gram-negative bacteremia. J Am Vet Med Assoc 200:1171-1884, 1992.
52. G-monomethyl-L-arginine are abolished in a canine shock model using high dose endotoxin. Res Commun Chem Pathol Pharmacol 78:57-68, 1992.
53. G-methyl-L-arginine, an inhibitor of nitric oxide formation acts synergistically to improve cardiovascular performance in endotoxic dogs. Crit Care Med 22:1825-1840, 1995.
54. Robertson F, Offner P, Ciceri D: Detrimental hemodynamic effects of nitric oxide synthase inhibition in septic shock. Arch Surg 129:149-156, 1994.
55. G-Monomethyl-L-arginine, an inhibitor of nitric oxide production, reverses interleukin-2 mediated hypotension in humans. Crit Care Med 23:1018-1024, 1995.
56. Meyer J, Traber L, Nelson S, et al: Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J Appl Physiol 73:324-328, 1992.
57. Meyer J, Lentz C, Stothert J, Traber L, Hemdon D, Traber D: Effects of nitric oxide synthesis inhibition in hyperdynamic endotoxemia. Crit Care Med 22:306-312, 1994.
58. Meyer J, Hinder F, Stothert J, et al: Increased organ blood flow in chronic endotoxemia is reversed by nitric oxide synthase inhibition. J Appl Physiol 76:2785-2793, 1994.
59. Lingnau W, McGuire R, Dehring D, et al: Changes in regional hemodynamics after nitric oxide synthase inhibition during ovine bacteremia. Am J Physiol 270:R207-R216, 1996.
60. Bone H, Traber L, Schenarts P, Spaulding T, Traber D: Hemodynamic effects of pyridoxalated hemoglobin polyoxyethylene conjugate (PHP) in conscious sheep during septic shock. Anesthesiology 83:A232, 1995.
61. Suffredini A, Fromm R, Parker M, et al: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321: 280-287, 1989.
62. Cobb P, Natanson C, Hoffman W: Differential hemodynamic effects of L-NMMA in endotoxemic and normal dogs. Am J Physiol 268:H1634-H1642, 1995.
63. Azimi G, Vincent, J-L: Ultimate survival from septic shock. Resuscitation 14:245-253, 1986.
64. Booke M, Meyer J, Lingnau W, Hinder F, Traber L, Traber D: Use of nitric oxide synthase inhibitors in animal models of sepsis. New Horizons 3:123-138, 1995.
65. Natanson C, Eichenholz P, Danner R, et al: Endotoxin and tumor necrosis factor challenges in the dog simulate the cardiovascular profile of human septic shock. J Exp Med 169:823-832, 1989.
66. Meadow W, Rudinsky B, Bell A, Hipps R: Effects of inhibition of endothelium-derived relaxing factor on hemodynamics and oxygen utilization during group B streptococcal sepsis in piglets. Crit Care Med 23:705-714, 1995.
67. Hibbs J, Taintor R, Vavrin Z, Rachlin E: Nitric oxide: A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157:87-94, 1988.
68. Kilbourn RG, Belloni P: Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin. J Natl Cancer lust 82:772-776, 1990.
69. Beasley D, Schwartz JH, Brenner BM: Interleukin-1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 87:602-608, 1991.
70. Kilbourn, RG: Septic shock: A central role for nitric oxide. In: Schlage G, Redl H (eds): 4th Wiggers Bernard Conference on Shock, Sepsis, and Organ Failure. Vienna, Austria: Springer-Verlag, 1995, pp 153-179.
71. MacMicking J, Nathan C, Horn G, et al: Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81:641-650, 1995.
72. Wei XQ, Charles I, Smith A, et al: Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375:408-411, 1995.
73. Laubach V, Shesely E, Smithies O, Sherman P: Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA 92:10688-10692, 1996.
74. G-methylarginine. Biochem Biophys Res Commun 170:96-103, 1990.
75. Lambert LE, Whitten JP, Baron BM, Cheng HC, Doherty NS, McDonald IA: Nitric oxide synthesis in the CNS, endothelium and macrophages differs in its sensitivity to inhibition by arginine analogues. Life Sci 48:69-75, 1991.
76. G-nitroarginine. Biochemistry 32:8512-8517, 1993.
77. Misko TP, Moore WM, Kasten TP, et al: Selective inhibition of the inducible NO synthase by aminoguanidine. Eur J Pharmacol 233:119-125, 1993.
78. Garvey EP, Oplinger JA, Tanoury GJ, et al: Potent and selective inhibition of human nitric oxide synthases. J Biol Chem 269:26669-26676, 1994.
79. Southan GJ, Szabó C, Thiemermann C: Isothioureas: Potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br J Pharmacol 114:510-516, 1995.
80. Southan GJ, Zingarelli B, O'Connor M, Salzman A, Szabó C: Spontaneous rearrangement of aminoalkylguanidines into mercaptoalkylguanidines: A novel class of nitric oxide synthase inhibitors with selectivity towards the inducible isoform. Br J Pharmacol 117:619-632, 1996.
81. Szabó C, Bryk R, Zingarelli B, et al: Pharmacological characterization of guanidinoethyldisulphide (CED), a novel inhibitor of nitric oxide synthase with selectivity towards the inducible isoform. Br J Pharmacol 118:1659-1668, 1996.
82. Thiemerman C, Rutten H, Wu CC, Vane JR: The multiple organ dysfunction by endotoxin in the rat: Attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol 116:2845-2851, 1995.
83. Arkovitz M, Garcia VF, Wispe JR, Szabó C: Selective inhibition of the inducible isoform of nitric oxide synthase inhibits endotoxin-induced pulmonary leak. J Pediatr Surg 31:1009-1015, 1996.
84. Wu CC, Chen SJ, Szabó CS, Thiemermann C, Vane JR: Aminoguanidine inhibits the delayed circulatory failure in endotoxic shock in the anaesthetized rat. BrJ Pharmacol 114:1666-1672, 1995.
85. Southan GJ, Szabó C: Commentary: Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 51:383-394, 1996.
86. Natanson C, Hoffman W, Suffredini A, Eichacker P, Danner R: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Int Med 120:771-783, 1994.
87. Lorente L, Landin L, Renés E, DePablo R, Liste D: Role of nitric oxide in the hemodynamic changes of sepsis. Crit Care Med 21:759-767, 1993.
88. Spain D, Wilson M, Garrison R: Nitric oxide synthase inhibition exacerbates sepsis-induced renal hypoperfusion. Surgery 116:322-331, 1994.
89. G-monomethyl-L-arginine HCl (L-NMMA: 546C88) improves survival in a conscious instrumented mouse model of endotoxic shock. Endothelium 3(Suppl):S116, 1995.
90. Laszlo F, Boughton-Smith N, Whittle BJR: Time-dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestine by nitric oxide synthase inhibitors. Br J Pharmacol 111:1309-1315, 1994.
91. Ochoa J, Curti B, Peitzman A, et al: Increased circulating nitrogen oxides after human tumor immunotherapy correlate with toxic hemodynamic changes. J Natl Cancer Inst 84:864-867, 1992.
92. Wong H, Carcillo J, Burkart G, Shah N, Janosky J: Increased serum nitrate and nitrite concentrations in children with sepsis syndrome. Crit Care Med 23:835-842, 1995.
93. Gomez-Jimenez J, Salgado A, Mourelle M, Martin M: L-arginine: Nitric oxide pathway in endotoxemia and human septic shock. Crit Care Med 23:253-258, 1995.
94. Hibbs J, Westenfelder C, Taintor R, et al: Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 89:867-877, 1992.
95. Haynes W, Noon J, Walker B, Webb D: L-NMMA increases blood pressure in man. Lancet 342:931-932, 1993.
96. Petros A, Bennett D, Vallance P: Effects of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338:1557-1558, 1991.
97. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P: Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28:34-39, 1994.
98. Lin PJ, Chang C-H, Chang J-P: Reversal of refractory hypotension in septic shock by inhibitor of nitric oxide synthase. Chest 106:626-629, 1994.
99. G-monomethyl-L-arginine, an inhibitor of nitric oxide synthase. Intensive Care Med 19: 227-231, 1993.
100. Lorente J, Landin L, De Pablo R, Renes E, Liste D: L-Arginine pathway in sepsis. Crit Care Med 21:1287-1295, 1993.
101. G-methyl-L-arginine in cancer patients with shock. Fourth international meeting: Biology of nitric oxide. Amelia Island, Florida: September 17-21, 1995.
102. Kilbourn R: Clinical trials of NOS inhibitors in shock. IBC's Fifth annual conference on nitric oxide: Moving towards the clinic. Philadelphia, PA: March 28-29, 1996.
103. Zaccardelli D, Graver R, Colice G: Hemodynamic effects of 546C88 (L-A-methylarginine HCL) in an open label, dose escalation study of patients with septic shock. 8th European congress of intensive care medicine. Athens, Greece: October 18-22, 1995.
104. ω-mono-methyl-L-arginine in ovine sepsis: Should a continuous infusion be initiated by bolus? Crit Care Med 23:A164, 1995.
105. Kilbourn RG, Griffith OW: Overproduction of nitric oxide in cytokine-mediated and septic shock. J Natl Cancer Inst 84:827-831, 1992.
106. Rhea G, Bodenham A, Mallick A, Prebelski R, Daily E: Vasopressor effects of diaspirin cross-linked hemoglobin (DCLHb) in critically ill patients. Crit Care Med 24:A39, 1996 (abstract).
107. Bone H, Booke M, Schenarts P, O'Connor M, Traber L, Traber D: Comparison of different doses of pyridoxylated hemoglobin polyethylene conjugate in the treatment of hyperdynamic sepsis. Crit Care Med 24:A27, 1996.
108. Bone H, Booke M, Traber L, Spaulding T, Traber D: Nitric oxide synthase inhibition versus nitric oxide scavenging in sepsis. Circulation 92:1-46, 1995.
109. Preiser J-C, Lejeune P, Roman A, et al: Methylene blue administration in septic shock: A clinical trial. Crit Care Med 23:259-264, 1995.
110. Schneider F, Lutun P, Hasselman M, Stoclet J, Tempe J: Methylene blue increases systemic vascular resistance in human septic shock. Intensive Care Med 18:309-311, 1992.
111. Daemen-Grubbels R, Groeneveld P, Groeneveld A, van Kamp G, Bronsveld W, Thijs LG: Methylene blue increases myocardial function in septic shock. Crit Care Med 23:1363-1370, 1995.
112. Paya D, Gray G, Stoclet J: Effects of methylene blue on blood pressure and reactivity to norepinephrine in endotoxemic rats. J Cardiovasc Pharmacol 21:926-930, 1993.
113. Keaney J, Puyana J, Francis S, Loscalzo C, Stamler J, Loscalzo J: Methylene blue reverses endotoxin-induced hypotension. Circ Res 74: 1121-1125, 1994.
114. Landin L, Lorente J, Renes E, Canas P, Jorge P, Liste D: Inhibition of nitric oxide synthase improves the vasoconstrictive effect of noradrenaline in sepsis. Chest 106:250-256, 1994.
115. Ogura H, Offner P, Saitoh D, Jordan A, Pruitt B, Cioffi W: The pulmonary effect of nitric oxide synthase inhibition following endotoxemia in a swine model. Arch Surg 129:1233-1239, 1994.
116. G-nitro-L-arginine infusion in porcine endotoxin shock. Crit Care Med 23:909-918, 1994.
117. Blum R, Carter S, Agre A: A clinical review of bleomycin: A new neoplastic agent. Cancer 31:903-914, 1973.
118. Samuels M, Howe C: Vinblastine in the management of testicular cancer. Cancer 25:1009-1017, 1970.
119. Logothetis C, Samuels M, Selig D, et al: Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors: Results with 100 patients. Am J Med 81:219-228, 1986.